Massive uganda study aims to uncover true sickle cell burden
NCT ID NCT06301893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to determine how common sickle cell trait and sickle cell disease are across Uganda by analyzing up to one million blood samples. Researchers want to create a detailed map of where the condition is most prevalent, which could help improve healthcare planning. The study includes people of all ages from different regions of Uganda.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide the first comprehensive map of sickle cell disease in Uganda, guiding public health efforts and resource allocation.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health outcomes, and results depend on accurate sampling across a large population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2013
- Expected to finish
-
Dec 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All Dried Blood Spot (DBS) samples collected from HIV exposed infants from all districts of Uganda from approximately February 2014 to March 2015 will be included in the primary analysis. Up to 1,000,000 additional samples may be collected during 2015 - 2030 following primary analysis based on surveillance findings.
- Ages
-
Up to 12 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Up to 1,000,000 samples may be collected during 2015 - 2030 following primary analysis based on surveillance findings. Exclusion Criteria: * Repeat samples on the same individuals during the study period will be excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Makerere University
RECRUITINGKampala, Uganda
-
Minister of Health
RECRUITINGKampala, Uganda
-
National Coordinator EID Program
RECRUITINGKampala, Uganda
-
Sickle Cell Clinic Department of Pediatrics & Child Health Mulago Hospital
RECRUITINGKampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding common pain drugs reduce morphine needs in sickle cell crises?
- Gene editing offers hope for a One-Time sickle cell cure
- Tiny biochip could reveal sickle cell severity
- Can a milder transplant cure sickle cell and thalassemia in adults?
- Can an antioxidant supplement calm sickle cell blood cells?
- Can a softer transplant cure sickle cell disease?